Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management

JAAD Case Rep. 2024 Oct 12:54:23-26. doi: 10.1016/j.jdcr.2024.09.021. eCollection 2024 Dec.

Gabriela Blanchard¹, Maël Blanchard¹, Pauline Bernard^{2

3}, Jacqueline Doms⁴, Begonia Cortés¹, Serge Boulinguez⁵, Emmanuella Guenova^{2

3

6

7}

¹ Division of Dermatology and Venereology, University Hospitals of Geneva, Geneva, Switzerland.
² Division of Dermatology and Venereology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
³ Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
⁴ Immunology and Allergy Division, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
⁵ Department of Dermatology, Centre Hospitalier Universitaire Toulouse, Toulouse, France.
⁶ Department of Dermatology, Hospital 12 de octubre, Medical School, University Complutense, Madrid, Spain.
⁷ University Institute and Clinic for Immunodermatology, Medical Faculty, Johannes Kepler University, Linz, Austria.

No abstract available

Keywords: CCR4; CTCL; IBD; Sézary syndrome; cutaneous T-cell lymphoma; inflammatory bowel disease; mogamulizumab; mycosis fungoides.

Publication types